Abstract:Xiao Luo, 1, 2, * Zhangya He, 1, 3, * Xiaomin Sun, 1, 3 Xinqian Gu, 1, 3 Wanyu Zhang, 1, 3 Jiayi Gao, 1, 3 Xiaomin Li, 1, 3 Ru Jia, 4 Junxiang Wei, 5 Yan Yu, 1, 3 Xiaoqin Luo 1, 3 1 Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, People's Republic of China; 3 Nutrition and Food Safety Engineering Research Center of Shaanxi Province, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 4 Department of Prosthodontics, Stomatological Hospital, College of Stomatology, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 5 Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China *These authors contributed equally to this work Correspondence: Xiaoqin Luo Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China Tel/Fax +86-29-82655111 Email luoxiaoqin2012@mail.xjtu.edu.cn Aim: Docosahexaenoic acid (DHA; C22; n-3) shows beneficial effects on Non-alcoholic fatty liver disease (NAFLD). Deacetylase Sirtuin1 (Sirt1) was reported to increase energy metabolism and decrease lipogenesis. Here, we investigated whether DHA plays a role in protecting against hepatic steatosis via Sirt1. Main Methods: Both in vivo and in vitro hepatic steatosis models were used: diet-induced obesity (DIO) model (middle-aged C57BL/6 mice fed a high-fat diet (HFD)) and palmitic acid (PA)-induced lipid accumulation cell model (HepG2 cells). Key Findings: In DIO mice, treatment with DHA (gavage supplementation) for 8 weeks not only inhibited the lipid accumulation, but also increased fatty acids (FA) oxidation and induced triglyceride export in liver. These changes were accompanied by attenuation of inflammation. Moreover, DHA reversed the HFD-induced reduction of Sirt1 in liver. Interestingly, the beneficial effects of DHA were reversed by lentivirus-mediated Sirt1 knockdown, accompanied with increased expression of markers of lipogenesis, inflammation and reduced FA oxidation. In HepG2 cells, DHA prevented the accumulation of PA-induced lipid droplets, the decrease of FA oxidation and the reduction of Sirt1 level. Inhibition of Sirt1 by sirtinol partially reversed the beneficial effects of DHA on PA-treated cells. Significance: DHA alleviated hepatic steatosis and reduced inflammation of liver in obese middle-aged mice by mechanisms involving Sirt1 activation. Keywords: non-alcoholic fatty liver disease, steatosis, docosahexaenoic acid, high-fat diet, Sirt1

Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy

Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress

Effects of dihydroartemisinin on the gut microbiome of mice

Dihydroartemisinin regulates lipid droplet metabolism in hepatic stellate cells by inhibiting lncRNA-H19-induced AMPK signal

HADHA alleviates hepatic steatosis and oxidative stress in NAFLD via inactivation of the MKK3/MAPK pathway

m6A methylation is required for dihydroartemisinin to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells

The Protective Effect of Dihydroartemisinin on Type 2 Diabetic Mice via Regulating Hepatic Glucose Output

Dihydroartemisinin improves hypercholesterolemia in ovariectomized mice via enhancing vectorial transport of cholesterol and bile acids from blood to bile

Dihydroartemisinin Attenuates Lipopolysaccharide-Induced Acute Lung Injury In Mice By Suppressing Nf-Kappa B Signaling In An Nrf2-Dependent Manner

Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway

Dihydroartemisinin modulated arachidonic acid metabolism and mitigated liver inflammation by inhibiting the activation of 5-LOX and COX-2

Therapeutic Role of Artemether in the Prevention of Hepatic Steatosis Through Mir-34A-5p/pparα Pathway

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice

Effects of DHA dietary intervention on hepatic lipid metabolism in apolipoprotein E-deficient and C57BL/6J wild-type mice

Dihydromyricetin Alleviates Nonalcoholic Fatty Liver Disease and Its Associated Metabolic Syndrome by Inhibiting Endoplasmic Reticulum Stress in LDLR−/− Mice Fed with a High-Fat and High-Fructose Diet

Reduction of NADPH Oxidase 4 in Adipocytes Contributes to the Anti-Obesity Effect of Dihydroartemisinin.

Dihydroartemisinin Ameliorates Learning and Memory in Alzheimer's Disease Through Promoting Autophagosome-Lysosome Fusion and Autolysosomal Degradation for Aβ Clearance.

Dihydroartemisinin Induces Endothelial Cell Autophagy through Suppression of the Akt/mTOR Pathway.

Dihydroartemisinin Induces Endothelial Cell Autophagy Through Suppression of the Akt/mTOR Pathway

Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+ T cells and modulating gut microbiota

DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model